Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review

Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: Case report and literature review

Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which is approved for the treatment of the relapsing and primary progressive multiple sclerosis (MS). It is extremely rarely associated with late-onset neutropenia (LON), as an...

Full description

Bibliographic Details
Main Authors: Jovićević Vanja, Bila Jelena, Mesaroš Šarlota, Pekmezović Tatjana, Drulović Jelena
Format: Article
Language:English
Published: Serbian Medical Society 2022-01-01
Series:Srpski Arhiv za Celokupno Lekarstvo
Subjects:
late onset neutropenia
ocrelizumab
multiple sclerosis
Online Access:http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200042J.pdf

Internet

http://www.doiserbia.nb.rs/img/doi/0370-8179/2022/0370-81792200042J.pdf

Similar Items